← The Wire
AVTXNasdaq
Avalo Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1534120
Developing IL-1β-based treatments for immune-mediated inflammatory diseases, including their lead candidate abdakibart for hidradenitis suppurativa
red 8-K · 90d
$776M
Market cap
$19.29
Last close
+6.0%
1D
+12.9%
5D
1.6M
Volume
Price · last 39 sessions+40.0%
May 4L $12.74 · H $22.87Jun 29
300
Total filings
Jun 23, 2026
Last filing
12/31
Fiscal year end
8-KExecutive ChangeJun 23, 20268-KCompany UpdateJun 16, 20268-KExecutive Change · Equity IssuanceJun 12, 20268-KExecutive Change · Shareholder VoteJun 8, 202610-Q10-QMay 13, 20268-KResults of OperationsMay 13, 20268-KMaterial Agreement · Results of OperationsMay 7, 2026424B5424B5May 7, 2026424B5424B5May 5, 20268-KCompany UpdateMay 5, 20268-KMaterial Agreement · Reg FD DisclosureApr 28, 2026DEFA14ADEFA14AApr 10, 2026DEF 14ADEF 14AApr 10, 20268-KExecutive ChangeMar 27, 202610-K10-KMar 23, 20268-KResults of OperationsMar 23, 20268-KResults of Operations · Company UpdateJan 12, 20268-KCompany UpdateDec 2, 202510-Q10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KCompany UpdateOct 29, 20258-KCompany UpdateOct 10, 20258-KExecutive Change · Company UpdateOct 1, 20258-KExecutive ChangeSep 22, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 7, 20258-KCompany UpdateJun 20, 20258-KExecutive Change · Company UpdateJun 18, 20258-KShareholder VoteJun 17, 20258-KMaterial Agreement · Agreement TerminatedJun 5, 2025424B5424B5Jun 5, 20258-KCompany UpdateJun 4, 202510-Q10-QMay 12, 20258-KResults of OperationsMay 12, 20258-KCompany UpdateMay 8, 2025DEFA14ADEFA14AMay 1, 2025DEF 14ADEF 14AMay 1, 20258-KExecutive Change · Company UpdateMar 26, 202510-K10-KMar 20, 20258-KResults of OperationsMar 20, 20258-KCompany UpdateJan 13, 20258-KExecutive Change · Company UpdateJan 2, 20258-KCompany UpdateDec 5, 2024SC 13GSCHEDULE 13GNov 14, 20248-KCompany UpdateNov 12, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 20248-KCompany UpdateOct 8, 2024SC 13GSC 13GOct 7, 20248-KCompany UpdateSep 9, 20248-KCompany UpdateSep 4, 2024SC 13GTHE SCHEDULE 13GAug 23, 2024SC 13GSC 13GAug 23, 2024SC 13GSC 13GAug 23, 20248-KExecutive Change · Shareholder VoteAug 14, 202410-Q10-QAug 12, 20248-KResults of OperationsAug 12, 20248-KCompany UpdateJul 30, 20248-KExecutive Change · Company UpdateJul 16, 202410-Q/A10-Q/AJul 11, 20248-KCompany UpdateJul 9, 2024DEFA14ADEFA14AJun 27, 2024DEF 14ADEF 14AJun 27, 20248-KExecutive Change · Company UpdateJun 24, 20248-K/ACompany UpdateJun 24, 20248-KCompany UpdateJun 24, 20248-K/ACompany UpdateJun 3, 20248-KDelisting NoticeMay 23, 2024SC 13GSC 13GMay 13, 202410-Q10-QMay 13, 20248-KResults of OperationsMay 13, 2024SC 13GSC 13GApr 23, 2024SC 13GSC 13GApr 5, 202410-K10-KMar 29, 20248-KResults of OperationsMar 29, 2024DEFA14ADEFA14AMar 28, 20248-KDelisting Notice · Executive ChangeMar 28, 20248-KCompany UpdateJan 31, 20248-KSecurity-Holder Rights · Bylaw AmendmentDec 28, 20238-KShareholder VoteDec 20, 2023
Insider Activity
In the 90 days to Mar 16, 2026: 1 sold $412K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Doyle MittieChief Medical Officer | Sell | 25,492 | $16.15 | $412K |
| Nov 14, 2025 | Goldman JonathanDirector | Sell | 8,200 | $14.35 | $118K |
| Nov 14, 2025 | Goldman JonathanDirector | Sell | 3,167 | $14.30 | $45K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance